{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T13:15:08Z","timestamp":1794921308876,"version":"4.9.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    A major unanswered question in the dementia field is whether cognitively unimpaired individuals who harbor both Alzheimer\u2019s disease neuropathological hallmarks (that is, amyloid-\u03b2 plaques and tau neurofibrillary tangles) can preserve their cognition over time or are destined to decline. In this large multicenter amyloid and tau positron emission tomography (PET) study (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20091,325), we examined the risk for future progression to mild cognitive impairment and the rate of cognitive decline over time among cognitively unimpaired individuals who were amyloid PET-positive (A\n                    <jats:sup>+<\/jats:sup>\n                    ) and tau PET-positive (T\n                    <jats:sup>+<\/jats:sup>\n                    ) in the medial temporal lobe (A\n                    <jats:sup>+<\/jats:sup>\n                    T\n                    <jats:sub>MTL<\/jats:sub>\n                    <jats:sup>+<\/jats:sup>\n                    ) and\/or in the temporal neocortex (A\n                    <jats:sup>+<\/jats:sup>\n                    T\n                    <jats:sub>NEO-T<\/jats:sub>\n                    <jats:sup>+<\/jats:sup>\n                    ) and compared them with A\n                    <jats:sup>+<\/jats:sup>\n                    T\n                    <jats:sup>\u2212<\/jats:sup>\n                    and A\n                    <jats:sup>\u2212<\/jats:sup>\n                    T\n                    <jats:sup>\u2212<\/jats:sup>\n                    groups. Cox proportional-hazards models showed a substantially increased risk for progression to mild cognitive impairment in the A\n                    <jats:sup>+<\/jats:sup>\n                    T\n                    <jats:sub>NEO-T<\/jats:sub>\n                    <jats:sup>+<\/jats:sup>\n                    (hazard ratio (HR)\u2009=\u200919.2, 95% confidence interval (CI)\u2009=\u200910.9\u201333.7), A\n                    <jats:sup>+<\/jats:sup>\n                    T\n                    <jats:sub>MTL<\/jats:sub>\n                    <jats:sup>+<\/jats:sup>\n                    (HR\u2009=\u200914.6, 95% CI\u2009=\u20098.1\u201326.4) and A\n                    <jats:sup>+<\/jats:sup>\n                    T\n                    <jats:sup>\u2212<\/jats:sup>\n                    (HR\u2009=\u20092.4, 95% CI\u2009=\u20091.4\u20134.3) groups versus the A\n                    <jats:sup>\u2212<\/jats:sup>\n                    T\n                    <jats:sup>\u2212<\/jats:sup>\n                    (reference) group. Both A\n                    <jats:sup>+<\/jats:sup>\n                    T\n                    <jats:sub>MTL<\/jats:sub>\n                    <jats:sup>+<\/jats:sup>\n                    (HR\u2009=\u20096.0, 95% CI\u2009=\u20093.4\u201310.6) and A\n                    <jats:sup>+<\/jats:sup>\n                    T\n                    <jats:sub>NEO-T<\/jats:sub>\n                    <jats:sup>+<\/jats:sup>\n                    (HR\u2009=\u20097.9, 95% CI\u2009=\u20094.7\u201313.5) groups also showed faster clinical progression to mild cognitive impairment than the A\n                    <jats:sup>+<\/jats:sup>\n                    T\n                    <jats:sup>\u2212<\/jats:sup>\n                    group. Linear mixed-effect models indicated that the A\n                    <jats:sup>+<\/jats:sup>\n                    T\n                    <jats:sub>NEO-T<\/jats:sub>\n                    <jats:sup>+<\/jats:sup>\n                    (\n                    <jats:italic>\u03b2<\/jats:italic>\n                    \u2009=\u2009\u22120.056\u2009\u00b1\u20090.005,\n                    <jats:italic>T<\/jats:italic>\n                    \u2009=\u2009\u221211.55,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001), A\n                    <jats:sup>+<\/jats:sup>\n                    T\n                    <jats:sub>MTL<\/jats:sub>\n                    <jats:sup>+<\/jats:sup>\n                    (\n                    <jats:italic>\u03b2<\/jats:italic>\n                    \u2009=\u2009\u22120.024\u2009\u00b1\u20090.005,\n                    <jats:italic>T<\/jats:italic>\n                    \u2009=\u2009\u22124.72,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001) and A\n                    <jats:sup>+<\/jats:sup>\n                    T\n                    <jats:sup>\u2212<\/jats:sup>\n                    (\n                    <jats:italic>\u03b2<\/jats:italic>\n                    \u2009=\u2009\u22120.008\u2009\u00b1\u20090.002,\n                    <jats:italic>T<\/jats:italic>\n                    \u2009=\u2009\u22123.46,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001) groups showed significantly faster longitudinal global cognitive decline compared to the A\n                    <jats:sup>\u2212<\/jats:sup>\n                    T\n                    <jats:sup>\u2212<\/jats:sup>\n                    (reference) group (all\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001). Both A\n                    <jats:sup>+<\/jats:sup>\n                    T\n                    <jats:sub>NEO-T<\/jats:sub>\n                    <jats:sup>+<\/jats:sup>\n                    (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001) and A\n                    <jats:sup>+<\/jats:sup>\n                    T\n                    <jats:sub>MTL<\/jats:sub>\n                    <jats:sup>+<\/jats:sup>\n                    (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.002) groups also progressed faster than the A\n                    <jats:sup>+<\/jats:sup>\n                    T\n                    <jats:sup>\u2212<\/jats:sup>\n                    group. In summary, evidence of advanced Alzheimer\u2019s disease pathological changes provided by a combination of abnormal amyloid and tau PET examinations is strongly associated with short-term (that is, 3\u20135 years) cognitive decline in cognitively unimpaired individuals and is therefore of high clinical relevance.\n                  <\/jats:p>","DOI":"10.1038\/s41591-022-02049-x","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T12:04:18Z","timestamp":1668081858000},"page":"2381-2387","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":483,"title":["Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1584-7477","authenticated-orcid":false,"given":"Rik","family":"Ossenkoppele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5218-3337","authenticated-orcid":false,"given":"Alexa","family":"Pichet Binette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7147-0112","authenticated-orcid":false,"given":"Ruben","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Strandberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9267-1930","authenticated-orcid":false,"given":"Sebastian","family":"Palmqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stomrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontus","family":"Tideman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Ohlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"J\u00f6gi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reisa","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8051-0558","authenticated-orcid":false,"given":"Vincent","family":"Dore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin L.","family":"Masters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5299-3628","authenticated-orcid":false,"given":"Bart N. M.","family":"van Berckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8766-6224","authenticated-orcid":false,"given":"Wiesje M.","family":"van der Flier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4458-113X","authenticated-orcid":false,"given":"William J.","family":"Jagust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Wiste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8178-6601","authenticated-orcid":false,"given":"Ronald C.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7916-622X","authenticated-orcid":false,"suffix":"Jr","given":"Clifford R.","family":"Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-7286","authenticated-orcid":false,"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"key":"2049_CR1","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"CR Jack Jr","year":"2016","unstructured":"Jack, C. R. Jr et al. A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87, 539\u2013547 (2016).","journal-title":"Neurology"},{"key":"2049_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack, C. R. Jr et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14, 535\u2013562 (2018).","journal-title":"Alzheimers Dement."},{"key":"2049_CR3","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","volume":"20","author":"B Dubois","year":"2021","unstructured":"Dubois, B. et al. Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the International Working Group. Lancet Neurol. 20, 484\u2013496 (2021).","journal-title":"Lancet Neurol."},{"key":"2049_CR4","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.jalz.2018.03.005","volume":"14","author":"R Brookmeyer","year":"2018","unstructured":"Brookmeyer, R. & Abdalla, N. Estimation of lifetime risks of Alzheimer\u2019s disease dementia using biomarkers for preclinical disease. Alzheimers Dement. 14, 981\u2013988 (2018).","journal-title":"Alzheimers Dement."},{"key":"2049_CR5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1474-4422(18)30029-2","volume":"17","author":"B Dubois","year":"2018","unstructured":"Dubois, B. et al. Cognitive and neuroimaging features and brain \u03b2-amyloidosis in individuals at risk of Alzheimer\u2019s disease (INSIGHT-preAD): a longitudinal observational study. Lancet Neurol. 17, 335\u2013346 (2018).","journal-title":"Lancet Neurol."},{"key":"2049_CR6","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1001\/jama.2017.6669","volume":"317","author":"MC Donohue","year":"2017","unstructured":"Donohue, M. C. et al. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA 317, 2305\u20132316 (2017).","journal-title":"JAMA"},{"key":"2049_CR7","doi-asserted-by":"publisher","first-page":"fcac017","DOI":"10.1093\/braincomms\/fcac017","volume":"4","author":"CR Jack Jr","year":"2022","unstructured":"Jack, C. R. Jr et al. Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk. Brain Commun. 4, fcac017 (2022).","journal-title":"Brain Commun."},{"key":"2049_CR8","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","volume":"71","author":"PT Nelson","year":"2012","unstructured":"Nelson, P. T. et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J. Neuropathol. Exp. Neurol. 71, 362\u2013381 (2012).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"2049_CR9","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele, R. et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain 139, 1551\u20131567 (2016).","journal-title":"Brain"},{"key":"2049_CR10","doi-asserted-by":"publisher","first-page":"e601","DOI":"10.1212\/WNL.0000000000006875","volume":"92","author":"R Ossenkoppele","year":"2019","unstructured":"Ossenkoppele, R. et al. Associations between tau, A\u03b2, and cortical thickness with cognition in Alzheimer disease. Neurology 92, e601\u2013e612 (2019).","journal-title":"Neurology"},{"key":"2049_CR11","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1001\/jama.2019.7437","volume":"321","author":"CR Jack Jr","year":"2019","unstructured":"Jack, C. R. Jr et al. Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. JAMA 321, 2316\u20132325 (2019).","journal-title":"JAMA"},{"key":"2049_CR12","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","volume":"21","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele, R., van der Kant, R. & Hansson, O. Tau biomarkers in Alzheimer\u2019s disease: towards implementation in clinical practice and trials. Lancet Neurol. 21, 726\u2013734 (2022).","journal-title":"Lancet Neurol."},{"key":"2049_CR13","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1007\/s00259-021-05258-7","volume":"48","author":"A Leuzy","year":"2021","unstructured":"Leuzy, A. et al. 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer\u2019s disease in the context of a structured 5-phase development framework. Eur. J. Nucl. Med. Mol. Imaging 48, 2121\u20132139 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2049_CR14","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","volume":"77","author":"AS Fleisher","year":"2020","unstructured":"Fleisher, A. S. et al. Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. JAMA Neurol. 77, 829\u2013839 (2020).","journal-title":"JAMA Neurol."},{"key":"2049_CR15","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1002\/alz.12321","volume":"17","author":"CM Moloney","year":"2021","unstructured":"Moloney, C. M., Lowe, V. J. & Murray, M. E. Visualization of neurofibrillary tangle maturity in Alzheimer\u2019s disease: a clinicopathologic perspective for biomarker research. Alzheimers Dement. 17, 1554\u20131574 (2021).","journal-title":"Alzheimers Dement."},{"key":"2049_CR16","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamaneurol.2020.0989","volume":"77","author":"A Leuzy","year":"2020","unstructured":"Leuzy, A. et al. Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders. JAMA Neurol. 77, 955\u2013965 (2020).","journal-title":"JAMA Neurol."},{"key":"2049_CR17","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2018.12917","volume":"320","author":"R Ossenkoppele","year":"2018","unstructured":"Ossenkoppele, R. et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA 320, 1151\u20131162 (2018).","journal-title":"JAMA"},{"key":"2049_CR18","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1001\/jamaneurol.2022.0676","volume":"79","author":"CB Young","year":"2022","unstructured":"Young, C. B. et al. Divergent cortical tau positron emission tomography patterns among patients with preclinical Alzheimer disease. JAMA Neurol. 79, 592\u2013603 (2022).","journal-title":"JAMA Neurol."},{"key":"2049_CR19","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ana.24546","volume":"79","author":"KA Johnson","year":"2016","unstructured":"Johnson, K. A. et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann. Neurol. 79, 110\u2013119 (2016).","journal-title":"Ann. Neurol."},{"key":"2049_CR20","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","volume":"89","author":"M Sch\u00f6ll","year":"2016","unstructured":"Sch\u00f6ll, M. et al. PET imaging of tau deposition in the aging human brain. Neuron 89, 971\u2013982 (2016).","journal-title":"Neuron"},{"key":"2049_CR21","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/brain\/awz019","volume":"142","author":"BA Gordon","year":"2019","unstructured":"Gordon, B. A. et al. Tau PET in autosomal dominant Alzheimer\u2019s disease: relationship with cognition, dementia and other biomarkers. Brain 142, 1063\u20131076 (2019).","journal-title":"Brain"},{"key":"2049_CR22","first-page":"748","volume":"140","author":"MJ Pontecorvo","year":"2017","unstructured":"Pontecorvo, M. J. et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain 140, 748\u2013763 (2017).","journal-title":"Brain"},{"key":"2049_CR23","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2021.1858","volume":"78","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele, R. et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol. 78, 961\u2013971 (2021).","journal-title":"JAMA Neurol."},{"key":"2049_CR24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ana.25395","volume":"85","author":"RA Sperling","year":"2019","unstructured":"Sperling, R. A. et al. The impact of amyloid-beta and tau on prospective cognitive decline in older individuals. Ann. Neurol. 85, 181\u2013193 (2019).","journal-title":"Ann. Neurol."},{"key":"2049_CR25","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","volume":"76","author":"BJ Hanseeuw","year":"2019","unstructured":"Hanseeuw, B. J. et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 76, 915\u2013924 (2019).","journal-title":"JAMA Neurol."},{"key":"2049_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01602-5","volume":"11","author":"SD Chen","year":"2021","unstructured":"Chen, S. D. et al. Staging tau pathology with tau PET in Alzheimer\u2019s disease: a longitudinal study. Transl. Psychiatry 11, 483 (2021).","journal-title":"Transl. Psychiatry"},{"key":"2049_CR27","doi-asserted-by":"publisher","first-page":"5888","DOI":"10.1038\/s41380-021-01263-2","volume":"26","author":"M Bucci","year":"2021","unstructured":"Bucci, M., Chiotis, K. & Nordberg, A. Alzheimer\u2019s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline. Mol. Psychiatry 26, 5888\u20135898 (2021).","journal-title":"Mol. Psychiatry"},{"key":"2049_CR28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13195-021-00937-x","volume":"13","author":"E Teng","year":"2021","unstructured":"Teng, E. et al. Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer\u2019s disease. Alzheimers Res. Ther. 13, 196 (2021).","journal-title":"Alzheimers Res. Ther."},{"key":"2049_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13195-021-00880-x","volume":"13","author":"D Biel","year":"2021","unstructured":"Biel, D. et al. Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals. Alzheimers Res. Ther. 13, 137 (2021).","journal-title":"Alzheimers Res. Ther."},{"key":"2049_CR30","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/brain\/awz090","volume":"142","author":"MJ Pontecorvo","year":"2019","unstructured":"Pontecorvo, M. J. et al. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer\u2019s disease dementia. Brain 142, 1723\u20131735 (2019).","journal-title":"Brain"},{"key":"2049_CR31","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.2967\/jnumed.118.221697","volume":"60","author":"H Cho","year":"2019","unstructured":"Cho, H. et al. Progressive tau accumulation in Alzheimer disease: 2-year follow-up study. J. Nucl. Med. 60, 1611\u20131621 (2019).","journal-title":"J. Nucl. Med."},{"key":"2049_CR32","doi-asserted-by":"crossref","unstructured":"Strikwerda-Brown, C. et al. Association of elevated amyloid and tau positron emission tomography signal with near-term development of Alzheimer disease symptoms in older adults without cognitive impairment. JAMA Neurology 79, 975\u2013985 (2022).","DOI":"10.1001\/jamaneurol.2022.2379"},{"key":"2049_CR33","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s00259-020-05118-w","volume":"48","author":"EE Wolters","year":"2021","unstructured":"Wolters, E. E. et al. Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer\u2019s disease in the context of a structured 5-phase biomarker development framework. Eur. J. Nucl. Med. Mol. Imaging 48, 2097\u20132109 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2049_CR34","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.trci.2017.10.004","volume":"3","author":"KV Papp","year":"2017","unstructured":"Papp, K. V., Rentz, D. M., Orlovsky, I., Sperling, R. A. & Mormino, E. C. Optimizing the preclinical Alzheimer\u2019s cognitive composite with semantic processing: the PACC5. Alzheimers Dement. (N Y) 3, 668\u2013677 (2017).","journal-title":"Alzheimers Dement. (N Y)"},{"key":"2049_CR35","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1093\/brain\/awaa180","volume":"143","author":"TA Pascoal","year":"2020","unstructured":"Pascoal, T. A. et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain 143, 2818\u20132830 (2020).","journal-title":"Brain"},{"key":"2049_CR36","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1212\/WNL.0000000000007831","volume":"93","author":"PS Insel","year":"2019","unstructured":"Insel, P. S. et al. Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology 93, e322\u2013e333 (2019).","journal-title":"Neurology"},{"key":"2049_CR37","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1093\/brain\/awaa209","volume":"143","author":"L Dumitrescu","year":"2020","unstructured":"Dumitrescu, L. et al. Genetic variants and functional pathways associated with resilience to Alzheimer\u2019s disease. Brain 143, 2561\u20132575 (2020).","journal-title":"Brain"},{"key":"2049_CR38","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/ana.23665","volume":"72","author":"P Vemuri","year":"2012","unstructured":"Vemuri, P. et al. Effect of lifestyle activities on Alzheimer disease biomarkers and cognition. Ann. Neurol. 72, 730\u2013738 (2012).","journal-title":"Ann. Neurol."},{"key":"2049_CR39","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.jalz.2018.07.219","volume":"16","author":"Y Stern","year":"2020","unstructured":"Stern, Y. et al. Whitepaper: defining and investigating cognitive reserve, brain reserve, and brain maintenance. Alzheimers Dement. 16, 1305\u20131311 (2020).","journal-title":"Alzheimers Dement."},{"key":"2049_CR40","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1001\/jamaneurol.2020.1741","volume":"77","author":"S Karanth","year":"2020","unstructured":"Karanth, S. et al. Prevalence and clinical phenotype of quadruple misfolded proteins in older adults. JAMA Neurol. 77, 1299\u20131307 (2020).","journal-title":"JAMA Neurol."},{"key":"2049_CR41","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ana.410270502","volume":"27","author":"ST DeKosky","year":"1990","unstructured":"DeKosky, S. T. & Scheff, S. W. Synapse loss in frontal cortex biopsies in Alzheimer\u2019s disease: correlation with cognitive severity. Ann. Neurol. 27, 457\u2013464 (1990).","journal-title":"Ann. Neurol."},{"key":"2049_CR42","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka, M. T. et al. Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol. 14, 388\u2013405 (2015).","journal-title":"Lancet Neurol."},{"key":"2049_CR43","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1136\/hrt.2007.120113","volume":"93","author":"C Junghans","year":"2007","unstructured":"Junghans, C. & Jones, M. Consent bias in research: how to avoid it. Heart 93, 1024\u20131025 (2007).","journal-title":"Heart"},{"key":"2049_CR44","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","volume":"26","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy, N. R. et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer\u2019s disease. Nat. Med. 26, 398\u2013407 (2020).","journal-title":"Nat. Med."},{"key":"2049_CR45","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze, S. et al. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat. Med. 26, 379\u2013386 (2020).","journal-title":"Nat. Med."},{"key":"2049_CR46","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","volume":"27","author":"S Palmqvist","year":"2021","unstructured":"Palmqvist, S. et al. Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat. Med. 27, 1034\u20131042 (2021).","journal-title":"Nat. Med."},{"key":"2049_CR47","first-page":"1797","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0, M. et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat. Med. 28, 1797\u20131801 (2022).","journal-title":"Nat. Med."},{"key":"2049_CR48","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000115751","volume":"30","author":"RO Roberts","year":"2008","unstructured":"Roberts, R. O. et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 30, 58\u201369 (2008).","journal-title":"Neuroepidemiology"},{"key":"2049_CR49","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1093\/cercor\/bht076","volume":"24","author":"R Ossenkoppele","year":"2014","unstructured":"Ossenkoppele, R. et al. Is verbal episodic memory in elderly with amyloid deposits preserved through altered neuronal function? Cereb. Cortex 24, 2210\u20132218 (2014).","journal-title":"Cereb. Cortex"},{"key":"2049_CR50","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.neuroimage.2015.03.069","volume":"144","author":"A Dagley","year":"2017","unstructured":"Dagley, A. et al. Harvard Aging Brain Study: dataset and accessibility. Neuroimage 144, 255\u2013258 (2017).","journal-title":"Neuroimage"},{"key":"2049_CR51","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3233\/ADR-210005","volume":"5","author":"C Fowler","year":"2021","unstructured":"Fowler, C. et al. Fifteen years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study: progress and observations from 2,359 older adults spanning the spectrum from cognitive normality to Alzheimer\u2019s disease. J. Alzheimers Dis. Rep. 5, 443\u2013468 (2021).","journal-title":"J. Alzheimers Dis. Rep."},{"key":"2049_CR52","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13195-018-0390-y","volume":"10","author":"RER Slot","year":"2018","unstructured":"Slot, R. E. R. et al. Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. Alzheimers Res. Ther. 10, 76 (2018).","journal-title":"Alzheimers Res. Ther."},{"key":"2049_CR53","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","volume":"13","author":"CR Jack Jr","year":"2017","unstructured":"Jack, C. R. Jr et al. Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease. Alzheimers Dement. 13, 205\u2013216 (2017).","journal-title":"Alzheimers Dement."},{"key":"2049_CR54","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2021.4654","volume":"79","author":"A Leuzy","year":"2022","unstructured":"Leuzy, A. et al. Biomarker-based prediction of longitudinal tau positron emission tomography in Alzheimer\u2019s disease. JAMA Neurol. 79, 149\u2013158 (2022).","journal-title":"JAMA Neurol."},{"key":"2049_CR55","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1093\/brain\/awab114","volume":"144","author":"D Berron","year":"2021","unstructured":"Berron, D. et al. Early stages of tau pathology and its associations with functional connectivity, atrophy and memory. Brain 144, 2771\u20132783 (2021).","journal-title":"Brain"},{"key":"2049_CR56","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","volume":"256","author":"RC Petersen","year":"2004","unstructured":"Petersen, R. C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256, 183\u2013194 (2004).","journal-title":"J. Intern. Med."},{"key":"2049_CR57","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1212\/WNL.0000000000004826","volume":"90","author":"RC Petersen","year":"2018","unstructured":"Petersen, R. C. et al. Practice guideline update summary: mild cognitive impairment: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 90, 126\u2013135 (2018).","journal-title":"Neurology"},{"key":"2049_CR58","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7, 263\u2013269 (2011).","journal-title":"Alzheimers Dement."},{"key":"2049_CR59","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2014.803","volume":"71","author":"MC Donohue","year":"2014","unstructured":"Donohue, M. C. et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 71, 961\u2013970 (2014).","journal-title":"JAMA Neurol."},{"key":"2049_CR60","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0896-6273(02)00569-X","volume":"33","author":"B Fischl","year":"2002","unstructured":"Fischl, B. et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 33, 341\u2013355 (2002).","journal-title":"Neuron"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02049-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02049-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02049-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T11:13:43Z","timestamp":1701342823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02049-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":60,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["2049"],"URL":"https:\/\/doi.org\/10.1038\/s41591-022-02049-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.05.23.22275241","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"18 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"O.H. has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer and Roche. In the past 2 years, he received consultancy\/speaker fees from AC Immune, Amylyx Pharmaceuticals, ALZpath, BioArctic, Biogen, Cerveau Technologies, Fujirebio, Genentech, Novartis, Roche and Siemens. R.O. gave a lecture in a symposium sponsored by GE Healthcare (fee paid to the institution). S.P. has served on scientific advisory boards and\/or given lectures in symposia sponsored by Biogen, Eli Lilly, Geras Solutions and Roche. W.J.J. consults for Eli Lilly, Eisai, Bioclinica and Prothena. C.R. is a scientific advisor to Cerveau Technologies, Prothena, Roche and has received research grants (paid to the institution) from Biogen, Eisai and Cerveau Technologies. R.C.P. has consulted for Roche, Merck, Biogen, Eisai, Genentech and Nestle and receives research funding from the National Institutes of Health (NIH). W.F. has performed contract research for Biogen and Boehringer Ingelheim, has been an invited speaker at Boehringer Ingelheim, Biogen, Danone, Eisai, WebMD Neurology (Medscape) and Springer Healthcare, is consultant to the Oxford Health Policy Forum CIC, Roche and Biogen, participated in the advisory boards of Biogen and Roche and is a member of the steering committee of PAVE and Think Brain Health (all funding\/fees were paid to the institution). C.R.J. serves on an independent data monitoring board for Roche, has served as a speaker for Eisai and consulted for Biogen but receives no personal compensation from any commercial entity. C.R.J. receives research support from the NIH and the Alexander Family Alzheimer\u2019s Disease Research Professorship of the Mayo Clinic. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}